NCT02204644View on ClinicalTrials.gov

The Study of the Efficacy and the Safety of Flumatinib vs Imatinib as First Line Treatment in Patients With CML

PHASE3CompletedINTERVENTIONAL
Enrollment

400

Participants

Timeline

Start Date

June 30, 2014

Primary Completion Date

June 30, 2017

Study Completion Date

December 31, 2017

Conditions
CML, CML-CP,MMR,TKI
Interventions
DRUG

Flumatinib 600mg qd

DRUG

Imatinib 400mg qd

Trial Locations (1)

300020

Hospital of Blood Diseases, Chinese Academy of Medical Sciences, Tianjin

Sponsors
All Listed Sponsors
lead

Jiangsu Hansoh Pharmaceutical Co., Ltd.

INDUSTRY